CN101972315A - Traditional Chinese medicinal composition and preparation method and use thereof - Google Patents
Traditional Chinese medicinal composition and preparation method and use thereof Download PDFInfo
- Publication number
- CN101972315A CN101972315A CN 201010296180 CN201010296180A CN101972315A CN 101972315 A CN101972315 A CN 101972315A CN 201010296180 CN201010296180 CN 201010296180 CN 201010296180 A CN201010296180 A CN 201010296180A CN 101972315 A CN101972315 A CN 101972315A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- accounts
- medicine extract
- medicine composition
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a traditional Chinese medicinal composition and a preparation method thereof and belongs to the technical field of traditional Chinese medicinal preparations. The traditional Chinese medicinal composition is prepared from 15 to 25 percent of traditional Chinese medicinal extract A, 40 to 50 percent of traditional Chinese medicinal extract B and 25 to 45 percent of pseudo-ginseng root. The traditional Chinese medicinal composition can inhibit or delay the islet beta-cell apoptosis and promote the restoration of the functions of the islet beta-cells, and also can be used for treating diabetic peripheral neuropathy.
Description
Technical field
The invention belongs to the Chinese medicine preparation technical field, be specifically related to a kind of Chinese medicine composition and preparation method and purposes.
Background technology
Diabetes (DM) are important modern diseases, can cause the chronic complicating diseases of a plurality of systems organ, cause dysfunction and depletion, become the main cause that disables, dies of illness.Think that in the past type 1 diabetes is because the autoimmune disease that causes of h and E, on mechanism based on cellular immunization, the inflammatory reaction factor, apoptosis-induced by oxyradical.Type 2 diabetes mellitus is because the disease of the insulin resistant that h and E causes, beta Cell of islet degeneration, depletion.1, the possible common mechanism of type 2 diabetes mellitus is induced the dysfunction and the apoptosis of islet cells for oxidative stress.Along with the further investigation of pair cell apoptosis and gene regulation and disease relationship, find that apoptosis has participated in the mechanism of diabetes closely.The Bcl-2 protein family is an albuminoid that is positioned at mitochondrial outer membrane, is divided into survivin and apoptotic proteins two classes.Anti-apoptotic proteins comprises Bcl-2 and Bcl-xL, and apoptotic proteins comprises Bax, Bad and Bid.Apoptotic proteins, apoptotic proteins enzyme and the mutual antagonism of anti-apoptotic proteins in the cell, mutual balance, when apoptotic effect was preponderated, aspartic acid cysteine proteinase (caspase-3) was activated, the path of blocking dna repairase DNA plerosis damage causes the irreversible apoptosis of cell.The islet function that the β apoptosis causes impaired in pathogenic process role be subjected to increasing attention.Recent one studies show that, no matter be the fat also type 2 diabetes mellitus patient of right and wrong obesity, the non-diabetic people suitable with its Body Mass Index compared, its beta Cell of islet number obviously reduces, islet cells apoptosis incidence rate is also apparently higher than normal population, and islets of langerhans regeneration and atomization there is no obvious difference between two groups of crowds.Whether the beta Cell of islet function is the determiner whether type 2 diabetes mellitus takes place normally; If beta Cell of islet can keep its compensatory capacity, type 2 diabetes mellitus can't take place, in case its compensatory capacity descends, then type 2 diabetes mellitus takes place gradually.Show according to the perspective diabetes study of Britain, the patient when being diagnosed as diabetes, the β cell function only remaining normal person 50%, descend in beta Cell of islet function every year thereafter with 4%～5% speed.In prediction on such basis, before diabetes diagnosis 10～15 years, the β cell function began to descend gradually.Diabetes have become the disease of worldwide serious harm health of people, and along with to the deepening continuously of diabetes basic research, the important function that the β apoptosis is risen in the morbidity of diabetes is found gradually.Adopt to suppress or delay the beta Cell of islet apoptosis, promote the means of beta Cell of islet functional rehabilitation, the control of diabetes is had huge meaning.
Diabetic peripheral neuropathy diabetes most common complication can cause the diabetics disability, disables even cause death.This disease mainly shows as distal limbs and torso portion numb pain and sensory disturbance, its pain characteristics acupuncture sample or burn sample, and the sample that lancinates, very person's pain makes the patient overwhelmed with sorrow as amputation, and life is lost interest, and loses confidence and is among the very big misery.It brings misery and burden not only for patient individual, family, causes serious economic problems also for social medical and health care system.Treatment at diabetic peripheral neuropathy is considered to present a great problem.Doctors often can only seek the alternative medicine of some approximate indications both at home and abroad, and opioid analgesics (as dolantin, lignocaine), tranquilizer (dilantin etc.), antidepressant (imipramine etc.), aldose reductase inhibitor (ARI etc.) and methycobal (vancomin) are arranged.These medicines are unsatisfactory through its effect of clinical verification, take for a long time in addition, are difficult to avoid such as toxic and side effects such as orthostatic hypotension, respiratory arrest, addiction, and most scholars have now advocated to limit the continuation use of these medicines.Some medical workers have adopted the medicine for the treatment of other disease to nurse one's health this disease, and as the medicine " gingko leaf preparation " of treatment cardiovascular and cerebrovascular disease, but the effect of these medicines is not remarkable.This also be for many years should disease sickness rate high, disable, the fatality rate major reason for higher.Diabetic peripheral neuropathy long-term damage patient's nerve (blood capillary), wreck patient's body, threaten patient's life, numerous doctors, comprise that World Health Organization (WHO) all appealing, wish to occur effectively treating medicine early, solve the difficult problem of this difficult diseases.
Summary of the invention
The purpose of this invention is to provide a kind of new Chinese medicine composition, beta Cell of islet apoptosis and beta Cell of islet functional rehabilitation are intervened and treated diabetes, and diabetic peripheral neuropathy is had therapeutical effect.
Technical scheme of the present invention is as follows:
A kind of Chinese medicine composition comprises Chinese medicine extract A, Chinese medicine extract B and Radix Notoginseng; Wherein the percentage by weight of each composition accounts for 15%-25% for Chinese medicine extract A, and Chinese medicine extract B accounts for 40%-50%, and Radix Notoginseng accounts for 25%-45%;
Described Chinese medicine extract A is to be made by the crude drug of following weight ratio: 312 parts of Radix Salviae Miltiorrhizaes, 625 parts of Rhizoma Corydalis (processed with vinegar);
Described Chinese medicine extract B is to be made by the crude drug of following weight ratio: 312 parts of the Radixs Astragali, 375 parts of Radix Paeoniae Rubra, 312 parts of Rhizoma Chuanxiongs, 312 parts on Flos Carthami, 250 parts of Lignum Sappans, 312 parts of Caulis Spatholobis;
The weight ratio of described Radix Notoginseng is 250 parts, makes through pulverizing.
Chinese medicine composition described in the technique scheme also comprises pharmaceutically acceptable carrier; The percentage by weight that comprises each composition in the Chinese medicine composition of pharmaceutically acceptable carrier accounts for 10%-20% for Chinese medicine extract A, and Chinese medicine extract B accounts for 25%-45%, and Radix Notoginseng accounts for 20%-30%, and pharmaceutically acceptable carrier accounts for 5%-45%.
Chinese medicine composition described in the technique scheme, wherein, the weight ratio of each composition accounts for 15% for Chinese medicine extract A in the described Chinese medicine composition, and Chinese medicine extract B accounts for 30%, and Radix Notoginseng accounts for 25%, and pharmaceutically acceptable carrier accounts for 30%.
Chinese medicine composition described in the technique scheme, wherein, described pharmaceutically acceptable carrier is selected from one or more the combination in dextrin, starch, cellulose, starch derivatives or the cellulose derivative.
Chinese medicine composition described in the technique scheme is in the preparation inhibition or delay the beta Cell of islet apoptosis, promote the purposes in the beta Cell of islet functional rehabilitation medicine.
The purposes of Chinese medicine composition described in the technique scheme in the medicine of preparation treatment diabetic peripheral neuropathy.
The preparation method of the Chinese medicine composition described in the technique scheme may further comprise the steps:
(1), the preparation of Chinese medicine extract A: get Radix Salviae Miltiorrhizae and add 6 times of amounts of ethanol, refluxed 2 hours, filter, reclaim ethanol, being evaporated to 60 ℃ of relative densities is 1.30～1.35 thick paste, and medicinal residues add 6 times of amounts of 40%-60% ethanol, refluxed 1.5 hours, filter, medicinal residues add 8 times of amounts of water, decoct 2 hours, filter, merging filtrate, decompression recycling ethanol, being concentrated into 60 ℃ of relative densities is 1.30～1.35 thick paste; Rhizoma Corydalis (processed with vinegar) adds the 60%-80% alcohol reflux three times, adding for the first time 4 times of amounts refluxed 3 hours, add for the second time 4 times of amounts and refluxed 2 hours, add 2 times of amounts for the third time and refluxed 1 hour, filter, merging filtrate, reclaim ethanol, be evaporated in the time of 60 ℃ relative density and be 1.30～1.35 thick paste, merge above-mentioned thick paste, drying promptly gets Chinese medicine extract A; Chinese medicine extract A in this step both can be ground into fine powder after drying and use, and also can directly use without the drying and crushing process;
(2), the preparation of Chinese medicine extract B: the Radix Astragali, Radix Paeoniae Rubra, Rhizoma Chuanxiong, Flos Carthami, Lignum Sappan and Caulis Spatholobi are mixed, decoct with water three times, adding for the first time 8 times of water gagings decocted 2 hours, add for the second time 6 times of water gagings and decocted 2 hours, add 4 times of water gagings for the third time and decocted 1 hour, filter, merging filtrate, being concentrated into 60 ℃ of relative densities is 1.30～1.35 thick paste, and drying promptly gets Chinese medicine extract B; Chinese medicine extract B in this step both can be ground into fine powder after drying and use, and also can directly use without the drying and crushing process;
(3), Radix Notoginseng powder is broken into fine powder;
(4), with after step (1), step (2), step (3) products therefrom mixing, drying, the pulverizing, add pharmaceutically acceptable carrier mix homogeneously again, granulate, drying promptly gets Chinese medicine composition.
Preparation method described in the technique scheme, wherein said pharmaceutically acceptable carrier are selected from one or more the combination in dextrin, starch, cellulose, starch derivatives or the cellulose derivative.
The dosage form of the Chinese medicine composition preparation described in the technique scheme, wherein dosage form is granule, capsule, tablet, electuary, suspensoid, pill or oral liquid.
The beneficial effect that Chinese medicine composition of the present invention and dosage form thereof have is: can effectively suppress or delay the beta Cell of islet apoptosis, promote the beta Cell of islet functional rehabilitation, can effectively treat diabetic peripheral neuropathy.
Figure of description:
Fig. 1 is an islets of langerhans structure under the light microscopic of rats in normal control group islets of langerhans HE dyeing back;
Fig. 2 is an islets of langerhans structure under the light microscopic of model group rat Langerhans islet HE dyeing back;
Fig. 3 is an islets of langerhans structure under the light microscopic of insulin Glargine group HE dyeing back;
Fig. 4 is an islets of langerhans structure under the light microscopic of low dose group rat Langerhans islet HE dyeing back;
Fig. 5 is an islets of langerhans structure under the light microscopic of middle dosage group rat Langerhans islet HE dyeing back;
Fig. 6 is an islets of langerhans structure under the light microscopic of high dose group rat Langerhans islet HE dyeing back;
Fig. 7 is that Bax expresses displayed map in model group rat endochylema and the karyon;
Fig. 8 is dosage group rat endochylema and the interior Bax expression of a karyon displayed map in the wooden red granule;
Fig. 9 is that Bax expresses displayed map in wooden red granule low dose group rat endochylema and the karyon;
Figure 10 is that Bax expresses displayed map in insulin Glargine group rat endochylema and the karyon;
Figure 11 is that Bcl-2 expresses figure in the model group rat karyon;
Figure 12 is that the interior Bcl-2 of dosage group rat karyon expresses figure in the wooden red granule;
Figure 13 is that Bcl-2 expresses figure in the wooden red granule low dose group rat karyon;
Figure 14 is that Bcl-2 expresses figure in the insulin Glargine group rat karyon.
The specific embodiment:
For making technical scheme of the present invention be convenient to understand, the present invention is further illustrated below in conjunction with the specific embodiment.
Embodiment 1:The preparation of Chinese medicine composition
(1), get Radix Salviae Miltiorrhizae 312g and add 6 times of amounts of ethanol, refluxed 2 hours, filter, reclaim ethanol, being evaporated to 60 ℃ of relative densities is 1.30～1.35 thick paste, and medicinal residues add 6 times of amounts of 50% ethanol, refluxed 1.5 hours, filter, medicinal residues add 8 times of amounts of water, decoct 2 hours, filter, merging filtrate, decompression recycling ethanol, being concentrated into 60 ℃ of relative densities is 1.30～1.35 thick paste; Rhizoma Corydalis (processed with vinegar) 625g adds 70% alcohol reflux three times, adds 4 times of amounts for the first time and refluxes 3 hours, adds 4 times of amounts for the second time and refluxes 2 hours, add 2 times of amounts for the third time and refluxed 1 hour, filter merging filtrate, reclaim ethanol, be evaporated in the time of 60 ℃ relative density and be 1.30～1.35 thick paste; Merge above-mentioned thick paste;
(2), with Radix Astragali 312g, Radix Paeoniae Rubra 375g, Rhizoma Chuanxiong 312g, Flos Carthami 312g, Lignum Sappan 250g, Caulis Spatholobi 312g mixes, and decocts with water three times, adding for the first time 8 times of water gagings decocted 2 hours, add for the second time 6 times of water gagings and decocted 2 hours, add 4 times of water gagings for the third time and decocted 1 hour, filter, merging filtrate, being concentrated into 60 ℃ of relative densities is 1.30～1.35 thick paste;
(3), Radix Notoginseng 250g is ground into fine powder;
(4), with step (1), step (2), step (3) products therefrom mix, dry, pulverize, adding pharmaceutically acceptable carrier dextrin to gross weight is 1000g, mixing is used 85% alcohol granulation, drying promptly gets Chinese medicine composition.Pharmaceutically acceptable carrier in this step also can be starch, cellulose, starch derivatives or cellulose derivative and the combination between them.
Embodiment 2:The preparation of Chinese medicine composition
Present embodiment identical with embodiment 1, difference is: in the step (4), account for 10% according to Chinese medicine extract A in the end product, Chinese medicine extract B accounts for 25%, Radix Notoginseng accounts for 20%, pharmaceutically acceptable carrier accounts for 45%, takes by weighing step (1), step (2), step (3) products therefrom and pharmaceutically acceptable carrier starch and cellulose mixtures, makes Chinese medicine composition.
Embodiment 3:The preparation of Chinese medicine composition
Present embodiment identical with embodiment 1, difference is: in the step (4), account for 20% according to Chinese medicine extract A in the end product, Chinese medicine extract B accounts for 45%, Radix Notoginseng accounts for 30%, pharmaceutically acceptable carrier accounts for 5%, takes by weighing the plain derivant of step (1), step (2), step (3) products therefrom and pharmaceutically acceptable carrier fibre, makes Chinese medicine composition.
Embodiment 4: the preparation of Chinese medicine composition dosage form
The Chinese medicine composition that makes among the embodiment 1～3, the formulation method commonly used according to this area is prepared into granule, capsule, tablet, electuary, suspensoid, pill or oral liquid.
Below by concrete test example further set forth Chinese medicine composition of the present invention (hereinafter to be referred as the beneficial effect that had when wooden red granule) being used to prepare inhibition or delaying beta Cell of islet apoptosis, promotion beta Cell of islet functional rehabilitation medicine:
To clean level SD rat barrier environment raises, ambient temperature is 20-25 ℃, humidity 40%～60%, 12h illumination/sky, after the laboratory adaptability fed for 1 week, after the rat fasting 24 hours, STZ (streptozotocin) is made into 1% concentration with 0.1%mmol/L citrate buffer (pH4.2,4 ℃), press abdominal cavity, 53mg/kg body weight dosage lower-left single injection, the tail vein is got blood after 72 hours, measures blood glucose with blood glucose meter, and all blood glucose 〉=16.7mmol/L include experiment in.Behind the glucostasis 3d, get into the mould rat and the DM rat is divided at random: dosage group, wooden red granule low dose group, insulin Glargine group in model group, wooden red granule high dose group, the wooden red granule, 10 every group according to table of random number.And be made as normal group with 10 of the normal rats that body weight, Mus are not complementary age.Modeling success administration in back 3 days.Normal group and model group: normal saline 10ml/kg irritates stomach, once a day.The heavy dose of treatment group of the red granule of wood by the dose,equivalent of people Mus dosage conversion administration of human, is given the red granule of 4.6g/kg.d wood and is irritated stomach; Middle dosage treatment group is given 2.3g/kg.d, low dose group is given the red granule of 1.15g/kg.d wood and irritated stomach once a day; The insulin Glargine group is given insulin Glargine 1U/100g lumbar injection, once a day by the dose,equivalent of people Mus dosage conversion administration of human.Get its pancreatic head part after 10% paraformaldehyde is fixed after irritating the anesthesia of 4 week of stomach back animal fasting carrying out then in 12 hours lumbar injection 20% urethane (0.5ml/100g), paraffin embedding, islets of langerhans morphological change and immunohistochemical staining observation of cell apoptosis situation are observed in the HE dyeing of section back.
(1) variation of rat cell under the light microscopic (HE X 400)
HE dyeing: show that as Fig. 1 see the islets of langerhans structural integrity under the rats in normal control group islets of langerhans mirror, islet cells is full rounded, cell space is plentiful, arranges closely; Show as Fig. 2, see rat Langerhans islet under DM group (model group) rat Langerhans islet mirror, out-of-shape, smaller volume, beta Cell of islet reduces; Show that as Fig. 4 wooden red granule low dose group also has similar performance, Islet cells reduces, the cell dense arrangement, and islets of langerhans β is less, out-of-shape, smaller volume; Show that as Fig. 3, Fig. 5 the dosage group has clear improvement than the DM group in insulin Glargine group and the wooden red granule, cell is rounded, marshalling, and beta Cell of islet increases than model group and low dose group; Show that as Fig. 6 high dose group is improved close with middle dosage group than the DM group, cell is arranged more neat, and beta Cell of islet is high-visible.
(2) wooden red granule is to the influence of Bax and Bcl-2
After 4 weeks, show that model group rat endochylema, and Bax great expression in the karyon are dark-brown as Fig. 7; Show that as Fig. 8 the dosage group is light brown in the wooden red granule; Show that as Fig. 9 wooden red granule low dose group dark brown granule is still more, but improve than the DM group; Show that as Figure 10 the insulin Glargine group is light brown.
Bcl-2 is then opposite, after 4 weeks, shows as Figure 11 that Bcl-2 is light brown in the model group rat karyon; Show that as Figure 12 the dosage group is dark-brown in the wooden red granule, express to have and increase than model group; Show as Figure 13, a small amount of brown particle of wooden red low dose group, but improvement is arranged than the DM group; Show that as Figure 14 the insulin Glargine group is dark-brown, express extensively.
Apoptosis comprises in diabetes and the complication generating process thereof playing an important role in multiple disease.A large amount of experiments are verified, and the Bcl-2 gene family has participated in the generation of beta Cell of islet apoptosis.Tree shrew DM behind injection STZ becomes in the mould person islets of langerhans anti-apoptosis-related protein molecule Bcl-2 to express to be starkly lower than blank group; and; the insulin expression level is proportionate in Bcl-2 expression and serum insulin levels and the islets of langerhans, and prompting Bcl-2 up-regulated may shield to the β cell.Discover that the Histological change of early stage trunk complication such as intimal thickening, proliferation of smooth muscle is seen in diabetes rat aorta HE dyeing; And Bcl-2 albumen descends in the expression of endotheliocyte and smooth muscle cell, and the Bax protein expression obviously increases.The prompting hyperglycemia may change the apoptosis regulation expression of gene, causes the decline of Bcl-2/Bax ratio, thereby has promoted aortic endothelial cell and smooth muscle cell apoptosis, finally may cause the generation of diabetes aortic disease.
In to treatment of diabetes, some experimental results show that Chinese patent medicine can control by the ratio of regulating Bcl-2/Bax treatment of diabetes.Can reduce islet cells Bax expression of gene, increase Islet cells Bcl-2 expression as squash polyoses, protect impaired beta Cell of islet, promote secretion of insulin.Diabetes rat diabetes 4 Bcl-2 down-regulated expression in pancreatic tissue during week in this research, and while Bax great expression, apoptosis appears in a large amount of cells in the pancreatic tissue, this apoptosis morphological study with us is consistent, illustrate that Bcl-2 down-regulated expression and Bax up-regulated are the important steps in the diabetes Apoptosis Mechanism, Bcl-2 family has participated in the adjustment process of diabetes rat islet cells apoptosis.
Its composition of the red granule of wood is polynary, and action range, benefiting QI for activating blood circulation can drive blood operation, improve blood viscosity, and blood stasis dispelling can suppress the islet cells apoptosis, and collateral dredging can pain relieving.Modern medicine study shows that part of diabetes mellitus patient's pancreas blood vessel has inaccessible obstructed sign.EnghoferL finds that the diabetes rat islets of langerhans inner blood circulatory disturbance after the STZ injection also is the reason that causes the β cell injury.The red granule of wood can the benefiting QI for activating blood circulation blood stasis dispelling, improves blood flow, promotes microcirculation, makes pancreatic duct unobstructed.The red granule of wood can improve Na
+-K
+-atpase activity significantly resists sciatic nerve, liver, kidney, pancreas, retinopathy; The red granule of wood also has the effect that reduces diabetes rat serum fructosamine content, suppresses the formation of AGE, reduces neural around the accumulating of AGE.The red granule energy of wood eliminating blood stasis to promote regeneration of blood, promoting blood circulation to remove obstruction in the collateral, the expression of rise Bcl-2 suppresses the expression of Bax, has significant inhibition beta Cell of islet apoptosis, recovers the effect of beta Cell of islet function.
The basic pathogenesis of diabetes shows as scorching impairment of YIN, and the cloudy QI consumed of decreasing causes deficiency of both QI and YIN.The deficiency of vital energy blood vessels stasis of blood stagnates, and venation is obstructed, and " stagnation of QI and blood may bring about pain " then is the main pathogenesis that causes diabetic peripheral neuropathy.The red granule of wood has benefiting QI for activating blood circulation, effects such as promoting tissue regeneration by removing blood stasis, removing obstruction in the collateral to relieve pain.The animal experiment study data shows, streptozotocin diabetes rat coccygeal nerve conduct velocity tool is improved significantly; Rising has remarkable inhibitory action to diabetes rat erythrocyte sorbitol content; Can significantly increase the pain threshold of diabetes rat; Unusual rising to stasis syndrome rat model blood plasma specific viscosity and packed cell volume has protective effect; Dichlorodiphenyl Acetate induced mice writhing response has obvious control action; Diabetic sciatic nerve, liver, kidney, pancreas, retinopathy there is protective effect; Can improve Na+-K+-ATP enzymatic activity in the diabetes rat nervous tissue; Can improve cAMP in the diabetes rat nervous tissue, cGMP content; Can improve the expression of diabetes rat nerve growth factor.
Human clinical's development test shows, wooden red granule therapy diabetic peripheral neuropathy determined curative effect, safety.Nerve conduction velocity is improved situation, obvious effective rate 61.54%, effective percentage 70.15%; Tcm syndrome curative effect, cure-remarkable-effectiveness rate are 23.69%, total effective rate 93.23%.
The above, it only is preferred embodiment of the present invention, be not that the present invention is done any formal and substantial restriction, all those skilled in the art, in not breaking away from the technical solution of the present invention scope, when can utilizing the above technology contents that discloses, and a little change of making, modify the equivalent variations with differentiation, be equivalent embodiment of the present invention; Simultaneously, all foundations essence technology of the present invention all still belongs in the scope of technical scheme of the present invention change, modification and the differentiation of any equivalent variations that above embodiment did.
Claims (9)
1. Chinese medicine composition, it is characterized in that: described Chinese medicine composition comprises Chinese medicine extract A, Chinese medicine extract B and Radix Notoginseng; Wherein the percentage by weight of each composition accounts for 15%-25% for Chinese medicine extract A, and Chinese medicine extract B accounts for 40%-50%, and Radix Notoginseng accounts for 25%-45%;
Described Chinese medicine extract A is to be made by the crude drug of following weight ratio: 312 parts of Radix Salviae Miltiorrhizaes, 625 parts of Rhizoma Corydalis (processed with vinegar);
Described Chinese medicine extract B is to be made by the crude drug of following weight ratio: 312 parts of the Radixs Astragali, 375 parts of Radix Paeoniae Rubra, 312 parts of Rhizoma Chuanxiongs, 312 parts on Flos Carthami, 250 parts of Lignum Sappans, 312 parts of Caulis Spatholobis;
The weight ratio of described Radix Notoginseng is 250 parts, makes through pulverizing.
2. Chinese medicine composition according to claim 1 is characterized in that: described Chinese medicine composition also comprises pharmaceutically acceptable carrier; The percentage by weight that comprises each composition in the Chinese medicine composition of pharmaceutically acceptable carrier accounts for 10%-20% for Chinese medicine extract A, and Chinese medicine extract B accounts for 25%-45%, and Radix Notoginseng accounts for 20%-30%, and pharmaceutically acceptable carrier accounts for 5%-45%.
3. Chinese medicine composition according to claim 2, it is characterized in that: the weight ratio of each composition accounts for 15% for Chinese medicine extract A in the described Chinese medicine composition that comprises pharmaceutically acceptable carrier, Chinese medicine extract B accounts for 30%, and Radix Notoginseng accounts for 25%, and pharmaceutically acceptable carrier accounts for 30%.
4. according to claim 2 or 3 described Chinese medicine compositions, it is characterized in that: described pharmaceutically acceptable carrier is selected from one or more the combination in dextrin, starch, cellulose, starch derivatives or the cellulose derivative.
5. the described Chinese medicine composition of arbitrary claim suppresses or delays the beta Cell of islet apoptosis, promotes the purposes in the beta Cell of islet functional rehabilitation medicine in preparation in the claim 1～4.
6. the purposes of the described Chinese medicine composition of arbitrary claim in the medicine of preparation treatment diabetic peripheral neuropathy in the claim 1～4.
7. the preparation method of the described Chinese medicine composition of arbitrary claim in the claim 2～4 may further comprise the steps:
(1), the preparation of Chinese medicine extract A: get Radix Salviae Miltiorrhizae and add 6 times of amounts of ethanol, refluxed 2 hours, filter, reclaim ethanol, being evaporated to 60 ℃ of relative densities is 1.30～1.35 thick paste, and medicinal residues add 6 times of amounts of 40%-60% ethanol, refluxed 1.5 hours, filter, medicinal residues add 8 times of amounts of water, decoct 2 hours, filter, merging filtrate, decompression recycling ethanol, being concentrated into 60 ℃ of relative densities is 1.30～1.35 thick paste; Rhizoma Corydalis (processed with vinegar) adds the 60%-80% alcohol reflux three times, adds 4 times of amounts for the first time and refluxes 3 hours, adds 4 times of amounts for the second time and refluxes 2 hours, add 2 times of amounts for the third time and refluxed 1 hour, filter merging filtrate, reclaim ethanol, be evaporated in the time of 60 ℃ relative density and be 1.30～1.35 thick paste; Merge above-mentioned thick paste, drying promptly gets Chinese medicine extract A;
(2), the preparation of Chinese medicine extract B: the Radix Astragali, Radix Paeoniae Rubra, Rhizoma Chuanxiong, Flos Carthami, Lignum Sappan and Caulis Spatholobi are mixed, decoct with water three times, adding for the first time 8 times of water gagings decocted 2 hours, add for the second time 6 times of water gagings and decocted 2 hours, add 4 times of water gagings for the third time and decocted 1 hour, filter, merging filtrate, being concentrated into 60 ℃ of relative densities is 1.30～1.35 thick paste, and drying promptly gets Chinese medicine extract B;
(3), Radix Notoginseng powder is broken into fine powder;
(4), step (1), step (2), step (3) products therefrom mixed, pulverize after, add pharmaceutically acceptable carrier mix homogeneously again, granulate, drying promptly gets Chinese medicine composition.
8. preparation method according to claim 7 is characterized in that: described pharmaceutically acceptable carrier is selected from one or more the combination in dextrin, starch, cellulose, starch derivatives or the cellulose derivative.
9. the dosage form of the described Chinese medicine composition of arbitrary claim preparation in the claim 2～4, it is characterized in that: described dosage form is granule, capsule, tablet, electuary, suspensoid, pill or oral liquid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102961804A CN101972315B (en) | 2010-09-29 | 2010-09-29 | Use of traditional Chinese medicinal composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102961804A CN101972315B (en) | 2010-09-29 | 2010-09-29 | Use of traditional Chinese medicinal composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101972315A true CN101972315A (en) | 2011-02-16 |
| CN101972315B CN101972315B (en) | 2012-09-05 |
Family
ID=43572245
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102961804A Active CN101972315B (en) | 2010-09-29 | 2010-09-29 | Use of traditional Chinese medicinal composition |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101972315B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1313119A (en) * | 2001-03-22 | 2001-09-19 | 营口奥达制药有限公司 | Medicinal particles for treating diabetic peripheral neuropathy |
| CN1424063A (en) * | 2002-12-18 | 2003-06-18 | 成都中汇制药有限公司 | Oral medicinal composition for treating diabetes |
| CN101647855A (en) * | 2008-08-13 | 2010-02-17 | 贵阳中医学院 | Traditional Chinese medicine preparation for treating diabetic neuropathy and preparation method thereof |
-
2010
- 2010-09-29 CN CN2010102961804A patent/CN101972315B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1313119A (en) * | 2001-03-22 | 2001-09-19 | 营口奥达制药有限公司 | Medicinal particles for treating diabetic peripheral neuropathy |
| CN1424063A (en) * | 2002-12-18 | 2003-06-18 | 成都中汇制药有限公司 | Oral medicinal composition for treating diabetes |
| CN101647855A (en) * | 2008-08-13 | 2010-02-17 | 贵阳中医学院 | Traditional Chinese medicine preparation for treating diabetic neuropathy and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101972315B (en) | 2012-09-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Verma et al. | Diabetes mellitus treatment using herbal drugs | |
| CN101357219B (en) | Medicine for treating chronic hepatitis B | |
| CN101411760B (en) | Novel use of plants in sorbus malus group of malus | |
| CN101647857B (en) | Chinese medicine composition for treating stein-leventhal syndrome and preparation method thereof | |
| US20180369308A1 (en) | Chinese herbal medicine composition having a function of relieving hypothyroidism, preparation method and use thereof | |
| CN101474361B (en) | Chinese medicine for treating cerebropathy | |
| CN104223297B (en) | A kind of schisandra chinensis health-care oral liquid of slow down aging and preparation method thereof | |
| CN100563630C (en) | The preparation method that is used for the treatment of the menoxenia Chinese medicine preparation | |
| CN102988905A (en) | Traditional Chinese medicine preparation for treating epilepsia and preparation method thereof | |
| Akhtar et al. | Hepatoprotective effect of Rheum emodi roots (Revand chini) and Akseer-e-Jigar against paracetamol-induced hepatotoxicity in rats | |
| CN100423754C (en) | Medicine for treating chronic alcoholic hepatopathy and its preparing method | |
| CN103055176B (en) | Traditional Chinese medicine for treating diabetes mellitus and preparation method thereof | |
| CN101972315B (en) | Use of traditional Chinese medicinal composition | |
| CN103385931B (en) | Blood-sugar-lowering medicine composition | |
| CN102028834B (en) | Compound Longxueji preparation and preparation method thereof | |
| CN104474461A (en) | Traditional Chinese medicine preparation for treatment of idiopathic trigeminal neuralgia and preparation method thereof | |
| CN109224038A (en) | A kind of Chinese medicine composition of the evodia rutaecarpa containing guiding drug and its preparation method and application for treating obstruction of collaterals by blood stasis type liver fibrosis | |
| CN111671795B (en) | Traditional Chinese medicine composition for treating diabetic peripheral neuropathy, traditional Chinese medicine preparation and application | |
| CN103705812B (en) | A kind of pharmaceutical composition for the treatment of gout and its production and use | |
| CN101991757B (en) | Chinese medicinal composition for reinforcing kidney and supporting yang and preparation method thereof | |
| CN104491101B (en) | Preparing method of traditional Chinese medicine preparation for treatment of chronic renal failure | |
| CN101972316B (en) | Traditional Chinese medicinal composition, use of traditional Chinese medicinal preparation | |
| CN108175801B (en) | Traditional Chinese medicine composition with chemical liver injury health care function and preparation method thereof | |
| CN101584851B (en) | Pharmaceutical composition for kidney nourishing, heart calming and nerve calming | |
| CN1315499C (en) | Medicine for treating diabetes and its complications and process for preparing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |